Clinical indications and future directions of carbon-ion radiotherapy: a narrative review DOI Creative Commons

H. Yoo,

Jeong‐Ju Yoo, Sang Gyune Kim

et al.

The Ewha Medical Journal, Journal Year: 2024, Volume and Issue: 47(4)

Published: Oct. 15, 2024

Carbon-ion radiotherapy (CIRT) offers superior dose distributions and greater biological effectiveness than conventional photon-based (RT). Due to its higher linear energy transfer relative effectiveness, CIRT is particularly effective against radioresistant tumors those located near critical organs. Since the first dedicated facility was established in Japan 1994, has demonstrated remarkable efficacy various malignancies, including head neck tumors, skull base upper cervical spine non-small-cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pancreatic cancer, prostate bone soft tissue sarcomas. This narrative review provides a comprehensive overview of current status CIRT, highlighting clinical indications future directions. According studies, achieves high local control rates with manageable toxicity across multiple types. For instance, (e.g., adenoid cystic mucosal melanoma), achieved exceeding 80%. In early-stage NSCLC, resulted over 90% minimal toxicity. Moreover, shown promise treating challenging cases HCC where therapies are limited. Nonetheless, global adoption remains limited due costs complexity. Future directions include conducting randomized controlled trials establish high-level evidence, integrating new technologies such as ultrahigh-dose-rate (FLASH) therapy, expanding facilities globally strategic planning cost-effectiveness analyses. If these challenges addressed, poised play transformative role treatment, improving survival quality life.

Language: Английский

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab‐Bevacizumab for Hepatocellular Carcinoma: Don't Ignore the Risk Factors! DOI Open Access
Shirin Salimi, Ken Liu

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Language: Английский

Citations

1
Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma DOI Creative Commons
Xinyi Li, Zhaohui Qin,

Haozhi Chen

et al.

International Journal of Immunopathology and Pharmacology, Journal Year: 2025, Volume and Issue: 39

Published: March 1, 2025

Objective: This study aims to develop a prognostic model for HCC based on TME-related factors. Introduction: Hepatocellular carcinoma (HCC) is characterized by poor prognosis, largely due the complex and heterogeneous interactions between stromal immune cells within tumor microenvironment (TME). Methods: Genome transcriptome data, as well clinical information of patients, were obtained from Cancer Atlas (TCGA) Gene Expression Omnibus (GEO). The TME score was evaluated using “ESTIMATE” R package. Differentially expressed genes (DEGs) associated with phenotype analyzed LIMMA R-package. Survival outcomes compared Kaplan–Meier curves log-rank test Cox proportional hazards model. Protein-Protein Interaction (PPI) networks integrated multivariate survival LASSO analyses utilized identify hub risk A nomogram predicting prognosis patients developed through four independent cohorts. Results: scores showed negative correlation progression in patients. We identified 50 core high connectivity PPI network, along 33 key DEGs HCC. Intersection analysis revealed six - CXCL8 , CXCL1 CCR7 IL7R MMP9 CD69 . these significantly overall clinicopathological characteristics Furthermore, demonstrated its ability discriminate healthy individuals peripheral blood mononuclear cells. Conclusion: have scoring gene panel that serve potential biomarker personalized immunotherapy non-invasive diagnostics

Language: Английский

Citations

0
The Real-World Prevalence of Esophagogastric Varices, Bleeding, Emergency Room Visits, and Hospitalization Among Patients with Advanced Hepatocellular Carcinoma in the United States: A Retrospective Cohort Study DOI Creative Commons
Neehar D. Parikh,

Noh Jin Park,

Michael Locker

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2025, Volume and Issue: Volume 12, P. 961 - 972

Published: May 1, 2025

Esophagogastric varices (EGV) and upper gastrointestinal bleeding are common potentially fatal complications in patients with advanced hepatocellular carcinoma (aHCC). We aimed to evaluate the real-world prevalence of EGV among aHCC population United States. This retrospective cohort study utilized IQVIA's PharMetrics Plus Health Plans Claims database between January 1, 2016, July 31, 2021 (study period). Adult an diagnosis who initiated systemic therapies were included, while those any secondary malignancies or prior liver transplant at baseline excluded. The date therapy initiation was index date; characteristics, procedures, clinical events interest captured during 12-month pre-index (baseline) period. Patients followed for outcomes (EGV- bleeding-related emergency room [ER] visits hospitalization) 6-month post-index Logistic regression conducted identify key predictors EGV- ER visit hospitalization. 904 included (mean age: 61.3 years; 75.3% male). Sorafenib (423 patients, 46.8%) most prescribed treatment. During entire period, 458 (50.7%) underwent esophagogastroduodenoscopy (EGD), whom 209 (45.6%) had EGV. Among 327 (36.2%) a EGD, 175 (53.5%) diagnosed 50 (15.3%) variceal bleeding; 141 (15.6% all patients) experienced ≥1 hospitalization post-index. There is high aHCC. presence EGV, bleeding, portal hypertension-related comorbidities associated increased risk subsequent hospitalizations Assessment stratification should be considered before initiating inform treatment decisions.

Language: Английский

Citations

0
Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review DOI Creative Commons
Hyuk Kim,

Yoon E. Shin,

Hyejin Yoo

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(9), P. 1422 - 1422

Published: Aug. 30, 2024

Immune check inhibitor (ICI) colitis is one of most common and adverse side effects ICI. However, there was no case report ulcerative (UC)-mimicking after atezolizumab use in hepatocellular carcinoma (HCC) to our knowledge.

Language: Английский

Citations

1
Clinical indications and future directions of carbon-ion radiotherapy: a narrative review DOI Creative Commons

H. Yoo,

Jeong‐Ju Yoo, Sang Gyune Kim

et al.

The Ewha Medical Journal, Journal Year: 2024, Volume and Issue: 47(4)

Published: Oct. 15, 2024

Carbon-ion radiotherapy (CIRT) offers superior dose distributions and greater biological effectiveness than conventional photon-based (RT). Due to its higher linear energy transfer relative effectiveness, CIRT is particularly effective against radioresistant tumors those located near critical organs. Since the first dedicated facility was established in Japan 1994, has demonstrated remarkable efficacy various malignancies, including head neck tumors, skull base upper cervical spine non-small-cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pancreatic cancer, prostate bone soft tissue sarcomas. This narrative review provides a comprehensive overview of current status CIRT, highlighting clinical indications future directions. According studies, achieves high local control rates with manageable toxicity across multiple types. For instance, (e.g., adenoid cystic mucosal melanoma), achieved exceeding 80%. In early-stage NSCLC, resulted over 90% minimal toxicity. Moreover, shown promise treating challenging cases HCC where therapies are limited. Nonetheless, global adoption remains limited due costs complexity. Future directions include conducting randomized controlled trials establish high-level evidence, integrating new technologies such as ultrahigh-dose-rate (FLASH) therapy, expanding facilities globally strategic planning cost-effectiveness analyses. If these challenges addressed, poised play transformative role treatment, improving survival quality life.

Language: Английский

Citations

0